title: Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
abstract: BACKGROUND
  Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy.
  
  
  METHODS
  Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80 mg/m(2). In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60 mg/m(2), was infused on day 8.
  
  
  RESULTS
  The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days.
  
  
  CONCLUSIONS
  Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.
authors.affiliation: Department of Surgery, Matsuyama Red Cross Hospital, 1 Bunkyoumachi, Matsuyama, Ehime 790-8524, Japan.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Sakaguchi
authors.forename: Akira
authors.initials: A
authors.lastname: Kabashima
authors.forename: Keishi
authors.initials: K
authors.lastname: Okita
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Ojima
authors.forename: Shinji
authors.initials: S
authors.lastname: Yamamura
authors.forename: Takashi
authors.initials: T
authors.lastname: Nishizaki
authors.forename: Hideya
authors.initials: H
authors.lastname: Tashiro
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Matsusaka
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid / Q000627:therapeutic use*; D010349:Patient Compliance; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D005641:Tegafur / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin